16-18 July 2018 | Boston
2 Weeks To Go!

Limited Passes Remaining – Secure Yours Now

Day One
Tuesday, July 17th 2018

Day Two
Wednesday, July 18th 2018

Designing Next Generation Immuno-therapies

Developing a Universal Immune Receptor Platform for Cancer Targeting

  • Daniel Powell Associate Professor of Pathology & Laboratory Medicine, University of Pennsylvania, School of Medicine

Profiling Murine Tumor Models to Improve Translational Predictive Confidence for Immune-Based Therapeutics

  • Tom Brennan Vice President, Pharmacology & Bioanalytics, Five Prime Therapeutics

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

  • Saad Kenderian Assistant Professor of Medicine and Oncology, Mayo Clinic

Morning Refreshments & Networking

Bridging the Gap Between In Vitro & In Vivo Oncology

11.00 Modelling the Tumor Microenvironment to Increase CAR T-Cell Efficacy in Solid Tumors: Strategies to Neutralize the Pro-Tumor Microenvironment

Matthew Hewitt, Principal Scientist & Director of Tumor Immunology & Microenvironment, Bellicum Pharmaceuticals

11.30 Active-Learning Strategies for High Content Screening of 3D Tumor Cell Models

Alejandro Amador, Scientific Leader, GlaxoSmithKline

Predicting In Vivo Pharmacology Response And Aiding Dose Translation

11.00 From PBPK to Quantitative Systems Pharmacology (QSP): Strategy and Applications in Oncology Discovery and Clinical development

Wen Lin, Senior Investigator I, Novartis Institutes for BioMedical Research

11.30 Design Criteria for Bispecific Antibodies: Learnings from Mathematical Modeling

John Rhoden, Senior Research Scientist, Eli Lilly & Co.